MedTrace Logo

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

NCT04199741 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.

Conditions

Interventions

DRUG

89Zr-DFO-SC16.56

Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.

DRUG

SC16.56, Phase I, Cohort 2

7.5mg

DRUG

SC16.56, Phase I, Cohort 3

22.5mg

DRUG

SC16.56, Phase II

Dose for Phase II will be determined by results from Phase I.

Sponsors & Collaborators

Principal Investigators

  • Mark P Dunphy, DO · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-11
Primary Completion
2026-06-11
Completion
2026-06-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04199741 on ClinicalTrials.gov